Bim suppresses the development of SLE by limiting myeloid inflammatory responses
FuNien Tsai,Philip J. Homan,Hemant Agrawal,Alexander V. Misharin,Hiam Abdala-Valencia,G. Kenneth Haines,Salina Dominguez,Christina L. Bloomfield,Rana Saber,Anthony Chang,Chandra Mohan,Jack Hutcheson,Anne Davidson,G.R. Scott Budinger,Philippe Bouillet,Andrea Dorfleutner,Christian Stehlik,Deborah R. Winter,Carla M. Cuda,Harris Perlman
DOI: https://doi.org/10.1084/jem.20170479
2017-11-07
Abstract:The Bcl-2 family is considered the guardian of the mitochondrial apoptotic pathway. We demonstrate that Bim acts as a molecular rheostat by controlling macrophage function not only in lymphoid organs but also in end organs, thereby preventing the break in tolerance. Mice lacking Bim in myeloid cells (LysMCreBimfl/fl) develop a systemic lupus erythematosus (SLE)–like disease that mirrors aged Bim−/− mice, including loss of marginal zone macrophages, splenomegaly, lymphadenopathy, autoantibodies (including anti-DNA IgG), and a type I interferon signature. LysMCreBimfl/fl mice exhibit increased mortality attributed to glomerulonephritis (GN). Moreover, the toll-like receptor signaling adaptor protein TRIF (TIR-domain–containing adapter-inducing interferon-β) is essential for GN, but not systemic autoimmunity in LysMCreBimfl/fl mice. Bim-deleted kidney macrophages exhibit a novel transcriptional lupus signature that is conserved within the gene expression profiles from whole kidney biopsies of patients with SLE. Collectively, these data suggest that the Bim may be a novel therapeutic target in the treatment of SLE.
immunology,medicine, research & experimental